Quick Dispatch:
Your igf-1 lr3 cancer risk Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy | Journal of Hematology & Oncology orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your igf-1 lr3 cancer risk Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy | Journal of Hematology & Oncology ships.
Need Help?
Questions about igf-1 lr3 cancer risk Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy | Journal of Hematology & Oncology, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for igf-1 lr3 cancer risk Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy | Journal of Hematology & Oncology in your area.
IGF-1 regulates cancer cell immune evasion in prostate cancer
21.25
Recent update on IGF-1/IGF-1R signaling axis as a promising therapeutic target for triple-negative breast cancer
25.49
Frontiers
27.24
IGF-1 LR3 in Aesthetic and Anti-Aging Medicine: Benefits and Risks
26.80
Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy | Journal of Hematology & Oncology
25.80
Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance
26.99
Frontiers
24.80
